Enhancement of radiation response of prostatic carcinoma by taxol: Therapeutic potential for late-stage malignancy

Balakrishna L Lokeshwar, S. M. Ferrell, N. L. Block

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Radiation therapy for advanced prostate cancer has dose-limiting complications and often results in limited tumor control. A combination of radiation and taxol, a potential radiation sensitizer, may enhance therapeutic efficacy at currently used individual doses. Human prostatic carcinoma lines in vitro, and Dunning rat prostatic adenocarcinoma in vivo, were treated with taxol and radiation individually, and in combination. Cytotoxicity of taxol was comparable between androgen sensitive and insensitive lines, with 50% growth inhibition at 9.6 to 12.7 nM. Combining agents increased cytotoxicity, with a dose modifying ratio of 1.8 at 0.1% survival. Flow cytometry showed an enhancement of radiation toxicity associated with taxol-induced cell cycle phase arrest at G2/M. Injection of taxol (4 mg/kg/day x 5), radiation dose fractionation (1.5 Gy/day x 5) and their combination significantly delayed delayed tumor growth. Adverse side effects were minimal. The results imply that combination of these agents may have clinical potential in prostate cancer treatment.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalAnticancer Research
Volume15
Issue number1
StatePublished - May 16 1995
Externally publishedYes

Fingerprint

Paclitaxel
Radiation
Carcinoma
Neoplasms
Prostatic Neoplasms
Dose Fractionation
Radiation-Sensitizing Agents
Therapeutics
Growth
Cell Cycle Checkpoints
Androgens
Flow Cytometry
Adenocarcinoma
Radiotherapy
Injections
Survival

Keywords

  • Chemotherapeutic agents
  • Prostate cancer
  • Radiation sensitization
  • Radiation therapy
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhancement of radiation response of prostatic carcinoma by taxol : Therapeutic potential for late-stage malignancy. / Lokeshwar, Balakrishna L; Ferrell, S. M.; Block, N. L.

In: Anticancer Research, Vol. 15, No. 1, 16.05.1995, p. 93-98.

Research output: Contribution to journalArticle

@article{16668b65c1e24c7c8c743541d3311cb3,
title = "Enhancement of radiation response of prostatic carcinoma by taxol: Therapeutic potential for late-stage malignancy",
abstract = "Radiation therapy for advanced prostate cancer has dose-limiting complications and often results in limited tumor control. A combination of radiation and taxol, a potential radiation sensitizer, may enhance therapeutic efficacy at currently used individual doses. Human prostatic carcinoma lines in vitro, and Dunning rat prostatic adenocarcinoma in vivo, were treated with taxol and radiation individually, and in combination. Cytotoxicity of taxol was comparable between androgen sensitive and insensitive lines, with 50{\%} growth inhibition at 9.6 to 12.7 nM. Combining agents increased cytotoxicity, with a dose modifying ratio of 1.8 at 0.1{\%} survival. Flow cytometry showed an enhancement of radiation toxicity associated with taxol-induced cell cycle phase arrest at G2/M. Injection of taxol (4 mg/kg/day x 5), radiation dose fractionation (1.5 Gy/day x 5) and their combination significantly delayed delayed tumor growth. Adverse side effects were minimal. The results imply that combination of these agents may have clinical potential in prostate cancer treatment.",
keywords = "Chemotherapeutic agents, Prostate cancer, Radiation sensitization, Radiation therapy, Taxol",
author = "Lokeshwar, {Balakrishna L} and Ferrell, {S. M.} and Block, {N. L.}",
year = "1995",
month = "5",
day = "16",
language = "English (US)",
volume = "15",
pages = "93--98",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Enhancement of radiation response of prostatic carcinoma by taxol

T2 - Therapeutic potential for late-stage malignancy

AU - Lokeshwar, Balakrishna L

AU - Ferrell, S. M.

AU - Block, N. L.

PY - 1995/5/16

Y1 - 1995/5/16

N2 - Radiation therapy for advanced prostate cancer has dose-limiting complications and often results in limited tumor control. A combination of radiation and taxol, a potential radiation sensitizer, may enhance therapeutic efficacy at currently used individual doses. Human prostatic carcinoma lines in vitro, and Dunning rat prostatic adenocarcinoma in vivo, were treated with taxol and radiation individually, and in combination. Cytotoxicity of taxol was comparable between androgen sensitive and insensitive lines, with 50% growth inhibition at 9.6 to 12.7 nM. Combining agents increased cytotoxicity, with a dose modifying ratio of 1.8 at 0.1% survival. Flow cytometry showed an enhancement of radiation toxicity associated with taxol-induced cell cycle phase arrest at G2/M. Injection of taxol (4 mg/kg/day x 5), radiation dose fractionation (1.5 Gy/day x 5) and their combination significantly delayed delayed tumor growth. Adverse side effects were minimal. The results imply that combination of these agents may have clinical potential in prostate cancer treatment.

AB - Radiation therapy for advanced prostate cancer has dose-limiting complications and often results in limited tumor control. A combination of radiation and taxol, a potential radiation sensitizer, may enhance therapeutic efficacy at currently used individual doses. Human prostatic carcinoma lines in vitro, and Dunning rat prostatic adenocarcinoma in vivo, were treated with taxol and radiation individually, and in combination. Cytotoxicity of taxol was comparable between androgen sensitive and insensitive lines, with 50% growth inhibition at 9.6 to 12.7 nM. Combining agents increased cytotoxicity, with a dose modifying ratio of 1.8 at 0.1% survival. Flow cytometry showed an enhancement of radiation toxicity associated with taxol-induced cell cycle phase arrest at G2/M. Injection of taxol (4 mg/kg/day x 5), radiation dose fractionation (1.5 Gy/day x 5) and their combination significantly delayed delayed tumor growth. Adverse side effects were minimal. The results imply that combination of these agents may have clinical potential in prostate cancer treatment.

KW - Chemotherapeutic agents

KW - Prostate cancer

KW - Radiation sensitization

KW - Radiation therapy

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0029000164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029000164&partnerID=8YFLogxK

M3 - Article

C2 - 7733649

AN - SCOPUS:0029000164

VL - 15

SP - 93

EP - 98

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -